



Universiteit
Leiden
The Netherlands

Risk assessment tools and adjuvant therapy for breast cancer

Noordhoek, I.

Citation

Noordhoek, I. (2025, December 10). *Risk assessment tools and adjuvant therapy for breast cancer*. Retrieved from <https://hdl.handle.net/1887/4284751>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4284751>

Note: To cite this publication please use the final published version (if applicable).

Risk assessment tools and adjuvant therapy for breast cancer

Iris Noordhoek

Design and lay-out: Iris Noordhoek

Art work: Anneke Patist

Printing and lay-out: Ridderprint | www.ridderprint.nl

The printing of this thesis was financially supported by the department of Medical Oncology of the Leiden University Medical Center and Stichting SBOH.

Risk assessment tools and adjuvant therapy for breast cancer

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op woensdag 10 december 2025
klokke 16:00 uur

door

Iris Noordhoek
geboren te Haarlem
in 1995

PROMOTORES

Prof. dr. J.E.A. Portielje

Prof. dr. G.J. Liefers

COPROMOTOR

Dr. J.R. Kroep

PROMOTIECOMMISSIE

Prof. dr. S.C. Linn (NKI-AvL)

Prof. dr. M.J.T.F.D. Vrancken-Peeters (NKI-AvL)

Prof. dr. A.J. Gelderblom

Prof. dr. J.A. van der Hage

Prof. dr. J. Wesseling

CONTENTS

Chapter 1	General introduction	7
Chapter 2	Higher ER load is not associated with better outcome in stage 1-3 breast cancer: descriptive overview of quantitative HR analysis in operable breast cancer	17
Chapter 3	Overestimation of late distant recurrences in high-risk patients with ER-positive breast cancer: validity and accuracy of the CTS5 risk score in the TEAM and IDEAL trials	35
Chapter 4	Breast Cancer Index (BCI) predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy	51
Chapter 5	Validation of the 70-gene signature test (MammaPrint) to identify breast cancer patients aged ≥ 70 years with ultralow risk of distant recurrence	71
Chapter 6	Daily oral ibandronate with adjuvant endocrine therapy in post-menopausal women with hormone receptor positive breast cancer: randomized phase 3 TEAM-IIB trial (BOOG 2006-04)	85
Chapter 7	General discussion and future perspectives	105
Appendices	Nederlandse samenvatting	120
	List of publications	132
	Curriculum vitae	134
	Dankwoord	135